Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do more targets allow more cancer treatments, or not?

European journal of cancer (Oxford, England : 1990) - 1 Jul 2023

Marchetti Paolo, Curigliano Giuseppe, Calabria Silvia, Piccinni Carlo, Botticelli Andrea, Martini Nello

Abstract excerpt

The three current oncology models (histological, agnostic and mutational) mainly differ in clinical, technological and organisational aspects, leading to different regulatory procedures and implications in antineoplastic therapy access by patients. Within the histological and agnostic models, Regulatory Agencies authorise target therapies and define their price, reimbursement, prescription and access based on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Genomics
Share to Medical Oncology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 37137204
DOI: 10.1016/j.ejca.2023.03.041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do more targets allow more cancer treatments, or not?PMID 37137204Read ↗

[The regulatory evaluation of tumor-agnostic drugs.]Semantic proximity Read ↗

[The tools for the governance of mutational oncology and agnostic drugs: from place in therapy to place in pathway.]Semantic proximity Read ↗

[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]Semantic proximity Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.Semantic proximity Read ↗

The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular ProfileSemantic proximity Read ↗

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologySemantic proximity Read ↗

Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testingSemantic proximity Read ↗

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.Semantic proximity Read ↗

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read ↗

Overview of Molecular Diagnostics in Irish Clinical OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.